$TECH · BIO-TECHNE Corp
This is Amendment No. 1 to Bio-Techne's Q1 FY2027 10-Q, filed solely to correct the signature page (conformed electronic signatures omitted); no other changes. For the quarter ended September 30, 2026, net sales were $299.7M (+4.6% YoY), gross margin 65.6%, operating income $36.6M, and net earnings $28.3M ($0.18 diluted EPS) versus $38.2M ($0.24) a year ago. The company is being acquired by Merck KGaA; shareholders approved the merger on September 23, 2026, with closing expected late 2026 or early 2027.
- Net sales $299.7M, up 4.6% YoY; organic revenue up 7% with business held-for-sale a 2% drag.
- Net earnings fell to $28.3M from $38.2M; diluted EPS $0.18 vs $0.24.
- GAAP gross margin flat at 65.6%; adjusted gross margin 69.3% vs 70.2%.
- Operating income declined to $36.6M from $47.7M on higher SG&A and R&D.
- Shareholders approved Merck KGaA merger Sept 23, 2026; close expected late 2026/early 2027.
Markets closed — no regular-session reaction yet; extended-hours move not captured here.
Quarterly results show margin compression, but the pending Merck KGaA acquisition is the dominant event for shareholders.
Life-science tools peer; the pending Merck KGaA takeout dominates the investment thesis over quarterly operating trends.
Merger closing remains subject to customary conditions and could slip beyond the late 2026/early 2027 target. Wilson Wolf forward contract may require ~$1B payment if second revenue/EBITDA milestone is hit.